首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   926篇
  免费   59篇
  国内免费   16篇
耳鼻咽喉   1篇
儿科学   23篇
妇产科学   21篇
基础医学   66篇
口腔科学   12篇
临床医学   93篇
内科学   188篇
皮肤病学   9篇
神经病学   42篇
特种医学   45篇
外科学   120篇
综合类   68篇
预防医学   55篇
眼科学   4篇
药学   121篇
  2篇
中国医学   29篇
肿瘤学   102篇
  2024年   1篇
  2023年   76篇
  2022年   152篇
  2021年   111篇
  2020年   96篇
  2019年   47篇
  2018年   43篇
  2017年   31篇
  2016年   29篇
  2015年   27篇
  2014年   72篇
  2013年   59篇
  2012年   59篇
  2011年   56篇
  2010年   42篇
  2009年   31篇
  2008年   13篇
  2007年   14篇
  2006年   10篇
  2005年   2篇
  2004年   7篇
  2003年   4篇
  2002年   3篇
  2001年   1篇
  2000年   2篇
  1999年   4篇
  1998年   5篇
  1997年   2篇
  1996年   2篇
排序方式: 共有1001条查询结果,搜索用时 796 毫秒
1.
2.
目的分析影响听神经瘤患者术后短期及长期面神经功能的危险因素。 方法回顾性分析厦门大学附属第一医院神经外科自2015年1月至2018年6月收治的62例听神经瘤患者的临床资料。于术后7 d及术后6个月对所有患者的面神经功能进行评估。收集可能与患者术后早期及长期面神经功能障碍存在相关性的因素,采用Logistic单因素与多因素回归对相关因素与患者术后短期及长期面神经功能的关系进行分析。 结果术后7 d,21例(33.9%)患者面神经功能正常,41例(66.1%)患者出现面神经功能损伤;术后6个月,49例(79.0%)患者面神经功能为正常,13例(21.0%)患者面神经功能损伤。Logistic单因素回归分析结果显示:肿瘤最大直径越大、肿瘤与面神经黏连越紧密,患者术后7 d发生面神经功能损伤的可能性越大(P=0.002、0.002);术前临床症状持续时间为患者术后6个月面神经功能障碍的危险因素(P=0.035)。Logistic多因素回归分析结果显示:肿瘤与面神经的黏连程度、肿瘤最大直径为患者术后7 d面神经功能障碍的独立危险因素(P=0.003、0.014);术前临床症状持续时间、肿瘤最大直径为患者术后6个月面神经功能障碍的独立危险因素(P=0.010、0.030)。 结论肿瘤与面神经的黏连越紧密、肿瘤最大直径越大,患者术后7 d发生面神经功能损伤的可能性越大。患者术前临床症状持续时间越长、肿瘤最大直径越大,术后6个月发生面神经功能损伤的可能性越大。  相似文献   
3.
目的建立中国成年患者的替考拉宁(teicoplanin,TEC)群体药动学(population pharmacokinetics,PPK)模型,考察TEC药动学参数的影响因素。方法前瞻性收集139例革兰阳性球菌感染患者静脉注射TEC后的222份常规监测血药浓度和相关信息,采用一级消除的一室模型进行数据拟合,并应用非线性混合效应模型(nonlinear mixed effect model,NONMEM)程序建立PPK模型。采用Bootstrap、正态预测分布误差法(normalized predictive distribution error,NPDE)进行最终模型评价。利用蒙特卡洛模拟法对给药方案进行优化。结果确定了肌酐清除率(creatinine clearance,CLcr)、白蛋白(albumin,ALB)为影响TEC清除率的主要因素。最终模型为:CL(L·h^-1)=1.24×(CLcr/77)0.564×31/ALB;V(L)=69.2。验证表明,模型稳定、有效,且有较好的预测效能。对于不同ALB和CLcr的多数患者起始负荷剂量400 mg/q12h,iv,3次,维持剂量400~800 mg·d^-1的给药方案可达有效治疗谷浓度。严重感染者需调整负荷剂量至800 mg/q12h,iv,3次,维持剂量400~800 mg·d^-1的给药方案来确保血药浓度达到15 mg·L^-1以上。结论本实验报道了CLcr、ALB对TEC清除率有显著影响,所建模型对TEC在中国成人患者中实现个体化给药具有重要应用价值。  相似文献   
4.
To explore the distribution of several bone metabolic indicators in type 2 diabetes patients (T2DM) with and without non-alcoholic fatty liver disease (NAFLD) and to preliminarily evaluate the relationship of bone metabolism with NAFLD in patients with T2DM. The hospitalized patients with T2DM were divided into the group of T2DM complicated with NAFLD and the group of T2DM alone according to the results of ultrasonic diagnosis. The general information and laboratory test data such as bone metabolism indexes of these patients were collected and the differences of the indexes between the 2 groups were compared. Furthermore, the independent influencing factors of NAFLD in patients with T2DM were analyzed. A total of 186 patients were included in the study. Compared with patients with T2DM only, patients with T2DM combined with NAFLD were characterized with younger age (p < 0.001), higher BMI (p = 0.016), ALT (p = 0.001), TG (p = 0.005), HOMA-IR (p = 0.005), and lower HDL-C (p = 0.031). Significant discrepancy of age (OR 1.052, p = 0.001), ALT (OR 0.964, p = 0.047), HOMA-IR (OR 0.801, p = 0.005), and T-PINP (OR 1.022, p = 0.008) was found using multivariate logistic regression model. Significant discrepancy of T-PINP was found in T2DM patients with and without NAFLD. Further studies are needed to explore whether T-PINP could be used as a predictor of fatty liver disease, osteoporosis, and other related complications in patients with T2DM.  相似文献   
5.
Pubertal suppression with gonadotropin-releasing hormone (GnRH) agonists in transgender and gender non-conforming (TGNC) youth may affect acquisition of peak bone mass. Bone marrow adipose tissue (BMAT) has an inverse relationship with bone mineral density (BMD). To evaluate the effect of pubertal suppression on BMAT, in this pilot study we prospectively studied TGNC youth undergoing pubertal suppression and cisgender control participants with similar pubertal status over a 12-month period. BMD was measured by dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. Magnetic Resonance T1 relaxometry (T1-R) and spectroscopy (MRS) were performed to quantify BMAT at the distal femur. We compared the change in BMD, T1-R values, and MRS lipid indices between the two groups. Six TGNC (two assigned female and four assigned male at birth) and three female control participants (mean age 10.9 and 11.7 years, respectively) were enrolled. The mean lumbar spine BMD Z-score declined by 0.29 in the TGNC group, but increased by 0.48 in controls (between-group difference 0.77, 95% CI: 0.05, 1.45). Similar findings were observed with the change in trabecular volumetric BMD at the 3% tibia site (-4.1% in TGNC, +3.2% in controls, between-group difference 7.3%, 95% CI: 0.5%-14%). Distal femur T1 values declined (indicative of increased BMAT) by 7.9% in the TGNC group, but increased by 2.1% in controls (between-group difference 10%, 95% CI: -12.7%, 32.6%). Marrow lipid fraction by MRS increased by 8.4% in the TGNC group, but declined by 0.1% in controls (between-group difference 8.5%, 95% CI: -50.2%, 33.0%). In conclusion, we observed lower bone mass acquisition and greater increases in BMAT indices by MRI and MRS in TGNC youth after 12 months of GnRH agonists compared with control participants. Early changes in BMAT may underlie an alteration in bone mass acquisition with pubertal suppression, including alterations in mesenchymal stem cells within marrow.  相似文献   
6.
BackgroundOsteoarthritis is an age-related disorder of bone-joint that causes pain and disability in middle and older people. This study aimed to investigate the potential effects of long non-coding RNA (lncRNA) THRIL on lipopolysaccharide (LPS)-induced osteoarthritis cell injury model (ATDC5 cell inflammatory injury), as well as the possible internal molecular mechanisms.MethodsCell viability and apoptosis were assessed using CCK-8 assay and Guava Nexin assay, respectively. Cell transfection was conducted to change the expression of THRIL and microRNA-125b (miR-125b) in ATDC5 cells. qRT-PCR was performed to detect the expression of THRIL, miR-125b and pro-inflammatory cytokines IL-6, TNF-α and monocyte chemotactic protein 1 (MCP-1) in ATDC5 cells. ELISA was used to measure the concentrations of IL-6, TNF-α and MCP-1 in culture supernatant of ATDC5 cells. Finally, the protein expression of key factors involved in cell apoptosis, inflammatory response, JAK1/STAT3 and NF-κB pathways were evaluated using western blotting.ResultsLPS significantly induced ATDC5 cell inflammatory injury and up-regulated the expression of THRIL. Overexpression of THRIL aggravated the LPS-induced ATDC5 cell inflammatory injury. Suppression of THRIL had opposite effects. Moreover, THRIL negatively regulated the expression of miR-125b in ATDC5 cells. miR-125b participated in the effects of THRIL overexpression on LPS-induced ATDC5 cell inflammatory injury. Furthermore, overexpression of THRIL enhanced the LPS-induced JAK1/STAT3 and NF-κB pathways activation by down-regulating miR-125b.ConclusionTHRIL exerted pro-inflammatory roles in LPS-induced osteoarthritis cell injury model. Overexpression of THRIL promoted LPS-induced ATDC5 cell inflammatory injury by down-regulating miR-125b and then activating JAK1/STAT3 and NF-κB pathways.  相似文献   
7.
8.
9.
陈一霞  卢美观 《医疗装备》2021,(5):165-166,168
目的探讨临床护理路径在椎管占位切除术及稳定性重建术后患者护理中的应用效果。方法选取2017年6月至2019年12月医院收治的116例行椎管占位切除术及稳定性重建术的患者作为研究对象,将2017年6月至2018年8月收治的58例患者设为对照组,2018年9月至2019年12月收治的58例患者设为观察组。对照组采用常规护理,观察组采用临床护理路径干预,比较两组住院天数、护理满意度、并发症发生情况。结果观察组住院天数短于对照组,护理满意度评分高于对照组,差异有统计学意义(P<0.05);观察组并发症发生率低于对照组,差异有统计学意义(P<0.05)。结论临床护理路径应用于椎管占位切除术及稳定性重建术后患者,可有效缩短患者的住院天数,提高护理满意度,降低并发症发生率。  相似文献   
10.
气囊扩张对74例良性溃疡伴幽门梗阻的长期疗效再探讨   总被引:1,自引:0,他引:1  
目的 再次评价气囊扩张对良性消化性溃疡伴幽门梗阻的长期疗效。方法 患者先行内科保守治疗 ,保守治疗不成功再行内镜下气囊扩张术。幽门螺杆菌阳性均给予根除治疗 ,抗溃疡病药物治疗至少一个月。结果  74例幽门梗阻中有 4 3例内科保守治疗成功 ,另 31例行气囊扩张术 (最大直径 1 2~ 1 4 mm) ,平均扩张次数为 1 .6 8±0 .83次。在随访 2 1 .0 6± 1 3.1 3个月中 ,梗阻的复发率分别为 4 .6 5 %和 1 6 .1 3% (P>0 .0 5 ) ,两组均未见并发症。结论 幽门梗阻气囊扩张术是一种安全、有效的方法 ,最终用多大直径的球囊扩张以梗阻症状解除为准 ,对良性溃疡伴幽门梗阻 ,即使是瘢痕型梗阻首选球囊扩张 ,如扩张不满意者才考虑手术治疗。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号